These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 15593007)

  • 1. The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.
    Robbins JB; Schneerson R; Trollfors B; Sato H; Sato Y; Rappuoli R; Keith JM
    J Infect Dis; 2005 Jan; 191(1):81-8. PubMed ID: 15593007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
    Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
    Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens.
    Scheifele DW; Ochnio JJ; Halperin SA
    Pediatr Infect Dis J; 2009 Nov; 28(11):985-9. PubMed ID: 19755930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
    Mertsola J; Van Der Meeren O; He Q; Linko-Parvinen A; Ramakrishnan G; Mannermaa L; Soila M; Pulkkinen M; Jacquet JM
    Clin Infect Dis; 2010 Sep; 51(6):656-62. PubMed ID: 20704493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.
    Ujiie M; Tsuzuki S; Suzuki M; Ota M; Suzuki T; Nomoto H; Yamamoto K; Saito S; Kokaze A; Kinoshita N
    Jpn J Infect Dis; 2021 Sep; 74(5):399-404. PubMed ID: 33518629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
    Gidengil CA; Sandora TJ; Lee GM
    Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan.
    Horiuchi Y; Takahashi M; Konda T; Ochiai M; Yamamoto A; Kataoka M; Toyoizumi H; Arakawa Y
    Jpn J Infect Dis; 2001 Oct; 54(5):167-80. PubMed ID: 11754154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.